Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program
EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug
Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial